Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration

Arcellx Shares Rise Premarket on Expanded Gilead Collaboration

Gilead Invests Further in Arcellx, Extends Collaboration

Dow Jones Ends Winning Streak; Cathie Wood Stock Soars On Earnings

Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat

Toast, Upstart shares sink while Take-Two’s stock rallies — and other stocks on the move

Gilead Sciences Results Beat Estimates

Gilead Sciences 3Q Results Beat Estimates

Gilead Sciences Raises 2023 Outlook

Gilead Sciences Sees FY EPS $4.55-EPS $4.75 >GILD

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

Assembly Biosciences Shares Soar Premarket on Gilead Pact

Gilead Taking Stake in Assembly Bio Under Antiviral Collaboration

Obesity Drugs Will Make Billions. But They Could Break the Healthcare System in the Process.

Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

Obesity Drugs Will Make Billions. But They Could Break the Healthcare System in the Process.

The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month

Health Care Roundup: Market Talk